JP5485979B2 - グルコピラノシド誘導体 - Google Patents

グルコピラノシド誘導体 Download PDF

Info

Publication number
JP5485979B2
JP5485979B2 JP2011503354A JP2011503354A JP5485979B2 JP 5485979 B2 JP5485979 B2 JP 5485979B2 JP 2011503354 A JP2011503354 A JP 2011503354A JP 2011503354 A JP2011503354 A JP 2011503354A JP 5485979 B2 JP5485979 B2 JP 5485979B2
Authority
JP
Japan
Prior art keywords
formula
compound
mixture
compounds
atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2011503354A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011516511A5 (https=
JP2011516511A (ja
Inventor
ツァクラキディス，クリストス
バイアー，ノーベルト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2011516511A publication Critical patent/JP2011516511A/ja
Publication of JP2011516511A5 publication Critical patent/JP2011516511A5/ja
Application granted granted Critical
Publication of JP5485979B2 publication Critical patent/JP5485979B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/04—Carbocyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2011503354A 2008-04-07 2009-03-17 グルコピラノシド誘導体 Expired - Fee Related JP5485979B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102008017590A DE102008017590A1 (de) 2008-04-07 2008-04-07 Glucopyranosidderivate
DE102008017590.0 2008-04-07
PCT/EP2009/001946 WO2009124638A1 (de) 2008-04-07 2009-03-17 Glucopyranosidderivate

Publications (3)

Publication Number Publication Date
JP2011516511A JP2011516511A (ja) 2011-05-26
JP2011516511A5 JP2011516511A5 (https=) 2012-05-10
JP5485979B2 true JP5485979B2 (ja) 2014-05-07

Family

ID=41051529

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011503354A Expired - Fee Related JP5485979B2 (ja) 2008-04-07 2009-03-17 グルコピラノシド誘導体

Country Status (9)

Country Link
US (1) US8399509B2 (https=)
EP (1) EP2260051B1 (https=)
JP (1) JP5485979B2 (https=)
AU (1) AU2009235786B2 (https=)
CA (1) CA2720586C (https=)
DE (1) DE102008017590A1 (https=)
ES (1) ES2394240T3 (https=)
IL (1) IL208065A (https=)
WO (1) WO2009124638A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010128152A1 (en) * 2009-05-07 2010-11-11 Novartis Ag Fused heterocyclic c-glycosides for the treatment of diabetes
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
WO2012165914A2 (en) * 2011-06-01 2012-12-06 Green Cross Corporation Novel diphenylmethane derivatives as sglt2 inhibitors
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9340521B2 (en) * 2013-03-18 2016-05-17 Green Cross Corporation Method for dual inhibition of SGLT1 and SGLT2 using diphenylmethane derivatives
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
WO2025160910A1 (en) * 2024-02-01 2025-08-07 New Wish Biotechnology Wuxi Co., Ltd. Indazole compound and pharmaceutical composition, preparation method and use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663336B1 (fr) 1990-06-18 1992-09-04 Adir Nouveaux derives peptidiques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
US6068834A (en) 1994-03-04 2000-05-30 The Procter & Gamble Company Skin lightening compositions
AU727775B2 (en) 1996-01-17 2000-12-21 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
AU719726B2 (en) 1996-12-26 2000-05-18 Tanabe Seiyaku Co., Ltd. Propiophenone derivatives and process for preparing the same
IL127296A (en) 1996-12-31 2003-01-12 Reddy Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them
WO1998031392A1 (en) 1997-01-17 1998-07-23 Drug Delivery System Institute, Ltd. Nephrotropic drugs
DE19726167B4 (de) 1997-06-20 2008-01-24 Sanofi-Aventis Deutschland Gmbh Insulin, Verfahren zu seiner Herstellung und es enthaltende pharmazeutische Zubereitung
PL338013A1 (en) 1997-07-16 2000-09-25 Novo Nordisk As Derivatives of condensed 1,2,4-thiadiazine, their production and application
CO4970713A1 (es) 1997-09-19 2000-11-07 Sanofi Synthelabo Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
JP2000080041A (ja) 1998-03-09 2000-03-21 Tanabe Seiyaku Co Ltd 医薬組成物
US6221897B1 (en) 1998-06-10 2001-04-24 Aventis Pharma Deutschland Gmbh Benzothiepine 1,1-dioxide derivatives, a process for their preparation, pharmaceuticals comprising these compounds, and their use
DE19845405C2 (de) 1998-10-02 2000-07-13 Aventis Pharma Gmbh Arylsubstituierte Propanolaminderivate und deren Verwendung
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
JP2002542245A (ja) 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
EP1177176B1 (en) 1999-04-28 2006-04-19 Aventis Pharma Deutschland GmbH Tri-aryl acid derivatives as ppar receptor ligands
WO2000066585A1 (en) 1999-04-30 2000-11-09 Neurogen Corporation 9H-PYRIMIDO[4,5-b]INDOLE DERIVATIVES: CRF1 SPECIFIC LIGANDS
GB9911863D0 (en) 1999-05-21 1999-07-21 Knoll Ag Therapeutic agents
DE60029446T2 (de) 1999-06-18 2007-02-08 Merck & Co., Inc. Arylthiazolidindione und aryloxazolidindion-derivate
BR0012752A (pt) 1999-07-29 2002-04-02 Lilly Co Eli Benzofuril piperazinas e benzofuril homopiperazinas: agonistas de serotonina
ATE264337T1 (de) 1999-08-31 2004-04-15 Kissei Pharmaceutical Glucopyranosyloxypyrazol-derivate, diese enthaltende arzneimittel und zwischenprodukte zu deren herstellung
HUP0202472A3 (en) 1999-09-01 2005-03-29 Aventis Pharma Gmbh Sulfonyl carboxiamide derivatives, method for their production and their use as medicaments
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
ES2254376T3 (es) 2000-03-17 2006-06-16 Kissei Pharmaceutical Co., Ltd. Derivados glucopiranosiloxibencilbenceno, preparaciones medicinales que los contienen e intermediarios para la preparacion de los indicados derivados.
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
AU5257401A (en) 2000-04-28 2001-11-12 Asahi Chemical Ind Novel bicyclic compounds
DE60115227T2 (de) 2000-05-11 2006-08-24 Bristol-Myers Squibb Co. Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
EP1289526A4 (en) 2000-05-30 2005-03-16 Merck & Co Inc MELANOCORTIN RECEPTOR AGONISTS
NZ523445A (en) 2000-06-29 2004-10-29 Abbott Lab Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents
US6872706B2 (en) 2000-09-29 2005-03-29 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxybenzylbenzene derivatives and medicinal compositions containing the same
ATE455785T1 (de) 2000-11-02 2010-02-15 Ajinomoto Kk Neue pyrazolderivate und diese enthaltende mittel gegen diabetes
AU2002223127A1 (en) 2000-11-30 2002-06-11 Kissei Pharmaceutical Co., Ltd. Intellectual Property Glucopyranosyloxybenzyl benzene derivatives, medicinal compositions containing the same and intermediates in the production thereof
CA2438593C (en) 2001-02-26 2010-09-21 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
CA2438595C (en) 2001-02-27 2011-08-09 Kissei Pharmaceutical Co., Ltd. Glucopyranosyloxypyrazole derivatives and medicinal use thereof
WO2002080936A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and ppar modulators
JP4590158B2 (ja) 2001-04-04 2010-12-01 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド グルコース再吸収阻害剤およびレチノイド−ｘ受容体モジュレーターを含んで成る併用療法
HRP20040199A2 (en) 2001-08-31 2005-04-30 Aventis Pharma Deutschland Gmbh Diaryl cycloalkyl derivatives, method for producing the same and the use thereof as ppar activators
DE10258008B4 (de) 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
DE10258007B4 (de) 2002-12-12 2006-02-09 Sanofi-Aventis Deutschland Gmbh Aromatische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
ES2567571T3 (es) * 2003-03-14 2016-04-25 Astellas Pharma Inc. Derivados de C-glucósido y sales de los mismos
EP1679965A4 (en) * 2003-08-01 2009-05-27 Janssen Pharmaceutica Nv SUBSTITUTED ANELLIERED HETEROCYCLIC C-GLYCOSIDES
AU2005219779B2 (en) * 2004-03-04 2011-04-14 Kissei Pharmaceutical Co., Ltd. Fused heterocycle derivative, medicinal composition containing the same, and medicinal use thereof
SE533267C2 (sv) 2008-12-16 2010-08-03 Sandvik Intellectual Property Skärkit, förfarande för tillverkning av skär, samt ett ur ett skärkit avskilt skär

Also Published As

Publication number Publication date
AU2009235786B2 (en) 2013-09-26
DE102008017590A1 (de) 2009-10-08
EP2260051A1 (de) 2010-12-15
AU2009235786A1 (en) 2009-10-15
CA2720586A1 (en) 2009-10-15
ES2394240T3 (es) 2013-01-23
IL208065A0 (en) 2010-12-30
EP2260051B1 (de) 2012-10-17
US20110028414A1 (en) 2011-02-03
IL208065A (en) 2014-03-31
CA2720586C (en) 2016-06-21
WO2009124638A1 (de) 2009-10-15
JP2011516511A (ja) 2011-05-26
US8399509B2 (en) 2013-03-19

Similar Documents

Publication Publication Date Title
JP5485979B2 (ja) グルコピラノシド誘導体
JP5519513B2 (ja) 糖尿病などの疾患を処置するためのイミダゾ［１，２−ａ］ピリミジン誘導体
JP5307718B2 (ja) １型および２型糖尿病を処置するためのＳＧＬＴ１およびＳＧＬＴ２阻害作用を有する３−アミノイミダゾ［１，２−ａ］ピリジン誘導体
JP5324436B2 (ja) Ｓｇｌｔ阻害剤としての３−アミノイミダゾ［１，２−ａ］ピリジン誘導体
US20070299065A1 (en) Tetrahydropyran Derivatives as Antidiabetics
US8119675B2 (en) Benzimidazole derivatives
JP5290990B2 (ja) インドリジン誘導体および抗糖尿病薬としてのこれらの使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120316

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120316

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131217

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140121

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140220

R150 Certificate of patent or registration of utility model

Ref document number: 5485979

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees